A phase I, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-534, a live, attenuated intranasal vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3), in healthy RSV and PIV3 seropositive 1-9 year-old children
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2009
At a glance
- Drugs MEDI 534 (Primary)
- Indications Parainfluenza virus infections; Respiratory syncytial virus infections
- Focus Adverse reactions
- 01 Jul 2009 Results published in The Pediatric Infectious Disease Journal.
- 02 May 2008 Results presented at PAS 2008.
- 30 Jul 2007 Status changed from in progress to completed.